Diaceutics. Personalized Medicine

Diaceutics is a highly focused business consulting and software application firm specializing in personalized medicine. Our mission is to improve overall return on investment in personalized medicine by providing pharmaceutical development teams the personalized medicine specific knowledge, evidence, tools and operational structure to effectively commercialize and successfully launch targeted therapies.

We greatly improve how our clients view the value propositions in personalized medicine and help them to optimize their commercial plans to realize that value. We also speak to the dissimilar understanding of how personalized medicine works by dispelling widely held but erroneous beliefs through the use of real world evidence and case studies, allowing our clients to build consensus on the most advantageous path forward.

Drawing from our years of research wholly focused on the personalized medicine space, considering specifically how diagnostic markets can be used to influence and shape therapy markets, we work with our clients on how best to ensure uptake and adoption of companion and other diagnostic tests to optimize and achieve their therapy goals. We ensure our clients leave no stone unturned and no option unconsidered in their quest to be leaders in the personalized medicine space.

Track Record

Diaceutics has a proven track record working with many of the top pharmaceutical companies in the US and Europe on dozens of different personalized medicine assets across multiple therapy areas – including oncology, infectious disease, metabolic disorders, sepsis and cardiac disease – and throughout the development lifecycle.

Diaceutics standardized and structured process to effectively commercialize and launch companion diagnostics alongside drug development is organized within the same functional frameworks with which every pharmaceutical drug development team works. This significantly reduces the learning curve to optimal personalized medicine planning, thus saving valuable time and resources.

Diaceutics content rich approach to commercializing companion and other diagnostics, delivered in a standardized yet adaptable process, provides demonstrable success in moving pharmaceutical asset teams from thinking of personalized medicine as merely a test and a drug, to a complete understanding of how a companion diagnostic or diagnostics can unlock the true value of a therapy market.

Demonstrated Value

In today’s challenging economy, no industry can afford to invest time and resources without some clear indication of the likely return on those investments. And like every other high cost, high-pressure industry, the pharmaceutical industry requires clear analytics and functional metrics to provide hard evidence of the value of its investments.

Diaceutics tracks and provides hard evidence of the value of investment in companion diagnostics to enable asset development teams to quickly identify and verify that their resource allocation in companion diagnostics are driving test adoption levels. In turn, this allows asset teams to provide quantifiable metrics to management that their investments in personalized medicine are providing appropriate returns.

On average, leveraging Diaceutics standardized and structured process to effectively commercialize and launch companion diagnostics has delivered greater than $100 return for every $1 invested, as described in our case studies.

Diaceutics Fusion™ is a proprietary, web-based, software application that provides a range of business intelligence and performance management applications used for personalized medicine planning, collaboration and decision-making. Utilizing easy to navigate route maps and an intuitive user interface, the software incorporates the six years of research, case studies, worktools, data sets, financial models and expertise that Diaceutics have built around the co-development and commercialization of companion and other diagnostic tests. Diaceutics Fusion™ standardizes the planning, analytical, decision and action steps needed to align the co-development and successful commercialization of companion and other diagnostics.

Diaceutics Fusion™ is much more than a simple project management tool or a knowledge database – it directly plugs the power of Diaceutics experience into the hands of the pharmaceutical client and allows deployment on a number of levels:

Provides personalized medicine leaders a tangible resource to provide therapy area leads and asset development teams seeking insight, expertise and best practices to guide their personalized medicine planning; Allows asset development teams to effortlessly work through the 11 key frameworks and decisions underpinning the additional 250 workstreams necessary to align co-development and commercialization of companion and other diagnostics. Provides the ability to revisit and, where necessary, reconsider and revise decisions, while at the same time immediately capturing and incorporating those new decisions into the existing plans for seamless, iterative planning; Creates a foundation upon which corporate knowledge of best practices and decisions in personalized medicine planning may be captured, stored and disseminated in order to build corporate knowledge and internal expertise around personalized medicine planning.

Click here for a demo of Diaceutics Fusion™

To learn more about the specific products offered in Diaceutics Fusion™, click on any of the subtabs above.
To learn more about how Diaceutics Fusion™ can be customized for your needs, click here.

*Roger Schank President/CEO, Socratic Arts Former Director, Yale Artificial Intelligence Project Founder, Institute of Learning Sciences, Northwestern University Co-Founder, Center for the Learning Sciences, Carnegie Mellon University